Specializing in cannabinoid-based medicines for a wide spectrum of disorders, St. Petersburg-based Biotica Pharmaceuticals Inc. recently appointed pharma industry executive P.C. Sundar as its new president and CEO.
Sundar brings more than three decades of executive practice in the pharmaceutical field. Prior to joining Biotica, he worked at Abbott Labs and Bayer and numerous Fortune 100 pharma companies. He will be instrumental in Biotica’s development of formulas designed to address a range of ailments, including neuropathic and chronic pain, cancer, Alzheimer's, Parkinson’s and esophagitis as well as developing immunological enhancements.
Previously, Sundar successfully brought numerous FDA-approved drugs to market and built collaborative ventures for the manufacturing companies. He has extensive experience in business growth and scaling, strategy development, operations, marketing, sales and innovation for international firms and broad brand portfolios.
Sundar’s experience in the pharma sector will position Biotica as a key figure in endocannabinoid drug discovery. Sundar earned his Ph.D. degree from Vanderbilt University.
Depending on the disease, Biotica’s therapies will use a BPRx platform to optimize a combination of photo and endocannabinoids to combat specific diseases. Currently operating from a single site in St. Petersburg, the company plans to construct a high-end research and development lab to augment its long-term growth.
Want to get notified whenever we write about FutureWorld Corp. ?
Sign-up Next time we write about FutureWorld Corp., we'll email you a link to the story. You may edit your settings or unsubscribe at any time.